Canadian biotech Milestone Pharmaceuticals Inc. took home C$13 million (US$13.3 million) in an equity financing round to boost development of its cardiovascular candidate, MSP-2017. The drug offers hope of a short-acting, as-needed treatment for episodes of paroxysmal supraventricular tachycardia (PSVT) that may allow patients to discontinue chronic therapy and stay out of the emergency room.